Skip to content

Clinical trials

Phase 1/2 Myeloproliferative Disorders trials in the United States

Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.

Filters: Condition: Myeloproliferative Disorders Phase: Phase 1/2 Country / region: United States Clear all

50 trials match Source: ClinicalTrials.gov registrations

Trials started per year

By phase, 2000 to 2026.

Trials started per year
CategoryTrials
20004
20011
20023
20033
20041
20052
20061
20071
20082
20102
20111
20121
20131
20143
20153
20162
20172
20182
20193
20202
20223
20242
20251
20261

Status

Trials by registry status. Select a bar to filter.

Trials by status
CategoryTrials
Completed29
Terminated6
Active, not recruiting5
Recruiting5
Withdrawn4
Suspended1

Top lead sponsors

A sponsor with a page on Pharma Observatory links to it.

Top lead sponsors
CategoryTrials
Fred Hutchinson Cancer Center7
M.D. Anderson Cancer Center6
Incyte Corporation4
Baylor College of Medicine2
Masonic Cancer Center, University of Minnesota2
National Cancer Institute (NCI)2
AbbVie1
Alliance for Clinical Trials in Oncology1
Cancer Treatment Centers of America1
Case Comprehensive Cancer Center1

Top conditions

MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.

Top conditions
CategoryTrials
Myeloproliferative Disorders50
Myelodysplastic Syndromes32
Leukemia, Myeloid, Acute27
Primary Myelofibrosis22
Leukemia19
Multiple Myeloma19
Leukemia, Myelomonocytic, Chronic18
Precursor Cell Lymphoblastic Leukemia-Lymphoma18
Lymphoma, Non-Hodgkin16
Leukemia, Lymphocytic, Chronic, B-Cell14

Trials

Showing 1 to 25 of 50. Each trial links to its page on Pharma Observatory.

Recently changed trials

Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.

No changes to these trials in the last 7 days.

Go deeper on Pharma Observatory

Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.